Scholars@Duke publication: Immunosuppression with bortezomib and anti-CD20 mAb is effective in reducing neutralizing antibodies to allow repeated AAV administration in mice

Immunosuppression with bortezomib and anti-CD20 mAb is effective in reducing neutralizing antibodies to allow repeated AAV administration in mice

Publication , Conference

Choi, SJ; Yi, J; Tedder, TF; Koeberl, DD; Kishnani, PS; Sun, B

Published in: Molecular Genetics and Metabolism

February 2021

Molecular Genetics and Metabolism

1096-7192

February 2021

132

S25 / S26

Elsevier BV

APA

Chicago

ICMJE

MLA

NLM

Choi, S. J., Yi, J., Tedder, T. F., Koeberl, D. D., Kishnani, P. S., & Sun, B. (2021). Immunosuppression with bortezomib and anti-CD20 mAb is effective in reducing neutralizing antibodies to allow repeated AAV administration in mice. In Molecular Genetics and Metabolism (Vol. 132, pp. S25–S26). Elsevier BV. https://doi.org/10.1016/j.ymgme.2020.12.041

Choi, Su Jin, John Yi, Thomas F. Tedder, Dwight D. Koeberl, Priya S. Kishnani, and Baodong Sun. “Immunosuppression with bortezomib and anti-CD20 mAb is effective in reducing neutralizing antibodies to allow repeated AAV administration in mice.” In Molecular Genetics and Metabolism, 132:S25–26. Elsevier BV, 2021. https://doi.org/10.1016/j.ymgme.2020.12.041.

Choi, Su Jin, et al. “Immunosuppression with bortezomib and anti-CD20 mAb is effective in reducing neutralizing antibodies to allow repeated AAV administration in mice.” Molecular Genetics and Metabolism, vol. 132, no. 2, Elsevier BV, 2021, pp. S25–26. Crossref, doi:10.1016/j.ymgme.2020.12.041.